Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms

Abstract

BACKGROUND: Over the past seven years, the use of long-acting forms of antipsychotic medication has significantly increased in Russia. Specifically, in Moscow, from 2016 to 2021, the proportion of prescribed injectable long-acting antipsychotics had increased more than sevenfold (from 3% to 23%). Studies have shown that the correct selection of target groups for such therapy can reduce the frequency of relapses requiring hospitalization, lower the costs of inpatient care, and shift the focus of therapy from multiple drug administrations to psychosocial work.

AIM: This study was aimed at evaluating changes over time in psychosocial functioning, as well as clinical and psychopathological manifestations, in patients with schizophrenia during early remission and while on therapy with different forms of paliperidone: oral paliperidone (OP), paliperidone palmitate administered once monthly (PP1M), and paliperidone palmitate administered once every three months (PP3M).

METHODS: The observational study included 155 patients: 54 patients who had been treated with another second-generation antipsychotic received OP, 50 patients who had been treated with another antipsychotic received PP1M injections, and 51 patients who had been in remission for four months after treatment with PP1M received PP3M. The duration of the follow-up period was 12 months. Assessment of personal and social functioning was conducted five times: before the start of treatment, and 3, 6, 9, and 12 months later.

RESULTS: Treatment in all groups led to a statistically significant reduction in the severity of positive symptoms (p <0.001). Hallucinations proved more susceptible to therapy (p <0.001), while persistent delusions showed greater treatment resistance. Significantly more patients in the PP1M and PP3M groups had completed the entire program (n=24; 48.0%, and n=30; 58.8%, respectively) compared to the OP group (n=11; 20.4%). The PP3M group demonstrated the highest treatment adherence, with the largest number of patients completing the study, and a similar rate of exacerbations or inadequate efficacy compared to the other groups.

CONCLUSION: Treatment with different forms of paliperidone provides a roughly equal pace reduction in the severity of schizophrenia, including positive and negative symptoms. The PP3M group had better adherence and the highest number of patients who fully completed the study.

Keywords

paliperidone palmitate / acute schizophrenia / remission of schizophrenia / psychosocial functioning / long-acting injectable antipsychotics

References

[1] Kurmyshev MV, Zaytseva MS, Kuzmenko AYu, et al. [The use of long acting antipsychotics in outpatient care]. Zhurnal nevrologii I psikhiatrii im. S.S. Korsakova. 2020;120(62):77-81. Russian. doi: 10.17116/jnevro202012006277

[2] Correll CU, Citrome L, Haddad PM, et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry, 2016;77(suppl 3):1-24. doi: 10.4088/JCP.15032su1

[3] Fang SC, Liao DL, Huang CY, et al. The effectiveness of long- acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. Human Psychopharmacol. 2020;35(3):e2729. doi: 10.1002/hup.2729

[4] Kane JM, Schooler NR, Marcy P, et al. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(12):1217-1224. doi: 10.1001/jamapsychiatry.2020.2076

[5] Lin CH, Chen FC, Chan HY, et al. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics. Int J Neuropsychopharmacol. 2019;22(9):541-547. doi: 10.1093/ijnp/pyz035

[6] Lin CH, Chen FC, Chan, HY, et al. A Comparison of Long-Acting Injectable Antipsychotics with Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients with Schizophrenia. Am J Geriatr Psychiatry. 2020;28(1):23-30. doi: 10.1016/j.jagp.2019.08.005

[7] Magliocco F, de Filippis R, Aloi M, et al. Second-generation long- acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. Int J Psychiatry Clin Pract. 2020;24(2):201-207. doi: 10.1080/13651501.2020.1737134

[8] Maestri TJ, Mican LM, Rozea H, et al. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission? Psychopharmacol Bull. 2018;48(3):8-15.

[9] Medrano S, Abdel-Baki A, Stip E, et al. Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacol Bull. 2018;48(4):25-61.

[10] Olayinka O, Oyelakin A, Cherukupally K, et al. Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital. Psychiatry J. 2019;2019:8629030 doi: 10.1155/2019/8629030

[11] Shah A, Xie L, Kariburyo F, et al. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Adv Ther. 2018;35(11):1994-2014. doi: 10.1007/s12325-018-0786-x

[12] Teitelbaum A, Kodesh A. [Long-acting injectable antipsychotics in schizophrenia]. Harefuah. 2019;158(7):453-457. Hebrew.

[13] Berezantsev AYu, Burygina LA, Levin ME. [Some current trends in the use of prolonged injectable antipsychotics in the conditions of modernization of the psychiatric service]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(62):61-67. Russian. doi: 10.17116/jnevro202012006261

[14] Burygina LA, Grigorieva DD, Golubev SA, et al. [Clinical and social characteristics, quality of life, adherence to therapy in IPA patients with schizophrenia spectrum disorders: a crosssectional study]. Psihiatriya. 2023;21(24):27-41. Russian doi: 10.30629/2618-6667-2023-21-4-27-41

[15] Kostyuk GP, Kurmyshev MV, Zajceva MS, et al. [Long-acting risperidone: analysis of 24 months of therapy in patients with frequent hospitalizations]. Social’naya i klinicheskaya psihiatriya. 2017;24(4):53-58. Russian.

[16] Lyubov EB, Chapurin SA, Churilin YuYu, et al. [Clinical, social and economic effectiveness of paliperidone palmitate in patients with the first episode of schizophrenia]. Social’naya i klinicheskaya psihiatriya. 2019;29(1):60-72. Russian.

[17] Joo SW, Shon SH, Choi G, et al. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study. Eur Neuropsychopharmacol. 2019;29(9):1051-1060. doi: 10.1016/j.euroneuro.2019.07.138

[18] Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015;21(9):754-768. doi: 10.18553/jmcp.2015.21.9.754

[19] Miura G, Misawa F, Kawade Y, et al. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study. J Clin Psychopharmacol. 2019;39(5):441-445. doi: 10.1097/JCP.0000000000001082

[20] Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379-1387. doi: 10.1093/schbul/sbm033

[21] Rubio JM, Taipale H, Correll CU, et al. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2020;50(8):1356-1367. doi: 10.1017/S0033291719001296

[22] Weiser M, Davis JM, Brown CH, et al. Differences in Antipsychotic Treatment Discontinuation Among Veterans with Schizophrenia in the U.S. Department of Veterans Affairs. Am J Psychiatry. 2021;178(10):932-940. doi: 10.1176/appi.ajp.2020.20111657

[23] Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12. doi: 10.1186/1744-859X-10-12

[24] Bossie CA, Sliwa JK, Ma YW, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry. 2011;11:79. doi: 10.1186/1471-244X-11-79

[25] Bozzatello P, Bellino S, Mancini I, et al. Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clin Drug Investig. 2019;39(2):169-178. doi: 10.1007/s40261-018-0734-1

[26] Brown B, Turkoz I, Mancevski B, et al. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428-438. doi: 10.1111/eip.12868

[27] Cai Q, Patel C, Kim E, et al. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Adv Ther. 2019;36(4):858-869. doi: 10.1007/s12325-019-00913-w

[28] Carpiniello B, Pinna F. Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia. Drug Des Devel Ther. 2016;10:1731-1742. doi: 10.2147/DDDT.S86301

[29] Fernandez-Miranda JJ, Diaz-Fernandez S, De Berardis D, et al. Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia. J Clin Med. 2021;10(7):1408. doi: 10.3390/jcm10071408

[30] Garcia-Carmona JA, Simal-Aguado J, Campos-Navarro MP, et al. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2021;36(1):18-24. doi: 10.1097/YIC.0000000000000339

[31] Gutiérrez-Rojas L, Sanchez-Alonso S, Garcia Dorado M, et al. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of PopulationBased Health Records in Spain. CNS Drugs. 2022;36(5):517-527. doi: 10.1007/s40263-022-00917-1

[32] Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi: 10.1016/S2215-0366(21)00039-0

[33] Marti'nez-Andrés JA, Garcia-Carmona JA. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Int Clin Psychopharmacol. 2020;35(3):163-169. doi: 10.1097/YIC.0000000000000300

[34] Najarian D, Sanga P, Wang S, et al. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. Int J Neuropsychopharmacol. 2022;25(3);238-251. doi: 10.1093/ijnp/pyab071

[35] Petrie D, Racki V, Gaco N, et al. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. J Child Adolesc Psychopharmacol. 2019;29(3):197-204. doi: 10.1089/cap.2018.0044

[36] Saglam Aykut D. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life. J Clin Psychopharmacol. 2019;39(1):57-62. doi: 10.1097/JCP.0000000000000993

[37] Segarra R, Recio-Barbero M, Saenz-Herrero M, et al. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP). Int J Neuropsychopharmacol. 2021;24(9):694-702. doi: 10.1093/ijnp/pyab021

[38] Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824-836. doi: 10.1016/S0140-6736(21)01997-8

[39] Alphs L, Bossie CA, Fu DJ, et al. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. Expert Opin Pharmacother. 2014;15(7):1029-1042. doi: 10.1517/14656566.2014.909409

[40] Kim S, Kim S, Koh M, et al. Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration. J Clin Psychiatry 2021;82(1):20m13446. doi: 10.4088/JCP.20m13446

[41] Savitz AJ, Xu H, Gopal S, et al. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol. 2017;32(6):329-336. doi: 10.1097/YIC.0000000000000190

[42] Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37-S41. doi: 10.1016/j.jclinepi.2013.01.012

[43] Basu A, Benson C, Alphs L. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3- Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia. J Manag Care Spec Pharm. 2018;24(8):759-768. doi: 10.18553/jmcp.2018.24.8.759

[44] Bell Lynum KS, Turkoz I, Kim E. Paliperidone palmitate once-every- 3-months in adults with early illness schizophrenia. Early Interv Psychiatry. 2019;13(3):667-672. doi: 10.1111/eip.12685

[45] Berwaerts J, Liu Y, Gopal S, et al. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(8):830-839. doi: 10.1001/jamapsychiatry.2015.0241

[46] Brasso C, Bellino S, Bozzatello P, et al. Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2767-2779. doi: 10.2147/NDT.S150568

[47] Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3

[48] Weiden PJ, Kim E, Bermak J, et al. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. J Clin Psychiatry. 2017;78(7):e813-e820. doi: 10.4088/JCP.16m11308

[49] Marder SR, Davis J M, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. doi: 10.4088/jcp.v58n1205

[50] Nash AI, Turkoz I, Savitz AJ, et al. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatr Dis Treat. 2019;15:731-737. doi: 10.2147/NDT.S194264

[51] Mathews M, Nuamah I, Savitz AJ, et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once- monthly paliperidone palmitate. Neuropsychiatr Disease Treat. 2018;14:2807-2816. doi: 10.2147/NDT.S175364

[52] Garcia-Portilla MP, Llorca PM, Maina G, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv Psychopharmacol. 2020;10:2045125320926347. doi: 10.1177/2045125320926347

[53] Garcia-Portilla MP, Benito Ruiz A, Gômez Robina F, et al. Impact on functionality of the paliperidone palmitate three- month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. Expert Opin Pharmacother. 2022;23(5):629-638. doi: 10.1080/14656566.2021.2023496

[54] Emond B, Joshi K, Khoury ACE, et al. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once- Every-3-Months Paliperidone Palmitate. Pharmacoecon Open. 2019;3(2):177-188. doi: 10.1007/s41669-018-0089-9

[55] Joshi K, Muser E, Xu Y, et al. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018;7(8):723-735. doi: 10.2217/cer-2018-0003

[56] Stahl S. Long-acting injectable antipsychotics: Shall the last be first? CNS Spectr. 2014;19(1):3-5. doi: 10.1017/S1092852913001016

[57] Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2020;101(4):323-329.

[58] Opler M, Fu DJ. Comments on the scoring guideline of the personal and social performance scale (PSP). Schizophr Res. 2014;152(1):304. doi: 10.1016/j.schres.2013.10.039

[59] Nafees B, van Hanswijck de Jonge P, Stull D, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res. 2012:140(1-3):71-76. doi: 10.1016/j.schres.2012.06.013

[60] Lee SC, Tang SF, Lu WS, et al. Minimal detectable change of the Personal and Social Performance scale in individuals with schizophrenia. Psychiatry Res. 2016;246:725-729. doi: 10.1016/j.psychres.2016.10.058

[61] Jelastopulu E, Giourou E, Merekoulias G, et al. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia. BMC Psychiatry. 2014;14:197. doi: 10.1186/1471-244X-14-197

[62] Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013. p. 743-744.

[63] Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. Washington: American Psychiatric Publishing; 2022.

[64] First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. 2013;201(9):727-729. doi: 10.1097/NMD.0b013e3182a2168a

[65] First MB, Gaebel W, Maj M, et al. An organization- and categorylevel comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. 2021;20(1):34-51. doi: 10.1002/wps.20825

[66] Berendsen S, van der Veen NM, van Tricht MJ, et al. Psychometric properties of the DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity. Schizophr Res. 2020;216:416-421. doi: 10.1016/j.schres.2019.10.059

[67] Liemburg E, Nienhuis F, Veling W. M95. DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity: Psychometric Properties. Schizophr Bull. 2020;46(Suppl 1):S170-S171. doi: 10.1093/schbul/sbaa030.407

[68] Jeong JH, Kim SW, Lee BJ, et al. The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study. Psychiatry Res. 2022;310:114420. doi: 10.1016/j.psychres.2022.114420

[69] Keeley JW, Gaebel W. Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11. Epidemiol Psychiatr Sci. 2018;27(3):219-224. doi: 10.1017/S2045796017000270

[70] Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology: Revised, 1976. Rockville: U.S. Department of Health, Education and Welfare, et al; 1976. p. 217-222.

[71] Berk M, Ng F, Dodd S, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14(6):979-983. doi: 10.1111/j.1365-2753.2007.00921.x

[72] Dunlop BW, Gray J, Rapaport MH. Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. Behav Sci (Basel). 2017;7(3):40. doi: 10.3390/bs7030040

[73] Alphs LD, Summerfelt A, Lann H, et al. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25(2):159-163.

[74] Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27(3):253-258. doi: 10.1016/0022-3956(93)90036-2

[75] Alphs L, Morlock R, Coon C, et al. The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training. Psychiatry (Edgmont). 2010;7(7):26-32.

Funding

Johnson & JohnsonJohnson & Johnson

RIGHTS & PERMISSIONS

Reznik A.M., Karpenko O.A., Shumakova E.A., Mudrak A.V., м A.V., Nazimova S.V., Saifulina A.M., Eliseenko A.M., Matvievskaya T.K., Khannanova A.N., Revenko V.I., Scherbakov D.V., Martynyuk Y.L., Arbuzov A.L., Yacenko O.A., Alekseeva P.N., Berdalin A.B., Burygina L.A.